Effects of glycaemic management on diabetic kidney disease

Table 3 Comparison of cardiovascular outcomes and mortality in randomised trials of intensive glucose control in type 2 diabetes participants with and without chronic kidney disease

	ACCORD		ADVANCE
	Total mortality	CV mortality	Total mortality	CV mortality
Overall study results (HR or RR)	1.22a (1.01-1.46)	1.35a (1.04-1.76)	0.93 (0.83-1.06)	0.88 (0.74-1.04)
Non-CKD participants (HR or RR)	1.08 (0.87-1.34)	1.14 (0.82-1.58)	0.74 (0.76-1.15)	0.78 (0.58-1.07)
CKD participants (HR or RR)	1.31a (1.07-1.60)	1.41a (1.05-1.89)	0.91 (0.72-1.14)	0.90 (0.67-1.22)

^aSignificant reduction with intensive glucose control. CV: Cardiovascular; CKD: Chronic kidney disease; ACCORD: Action to control cardiovascular risks in diabetes; ADVANCE: Action in diabetes and vascular disease: Pretrex and diamicron MR controlled evaluation; HR: Hazard ratio; RR: Relative risk.